Sloan Paul A
University of Kentucky Medical Center, Lexington, KY 40536, USA.
Curr Pain Headache Rep. 2007 Aug;11(4):283-9. doi: 10.1007/s11916-007-0205-5.
Most patients with cancer pain achieve good analgesia using traditional analgesics and adjuvant medications; however, an important minority of patients (2% to 5%) suffers from severe and refractory cancer pain. For these individuals, spinal analgesics (intrathecal or epidural) provide significant hope for pain relief over months or years of treatment to help improve quality of life. Spinal analgesics have been suggested as the fourth step in the World Health Organization guidelines in the management of cancer pain, and thus the pain physician should be familiar with principles of use. Most patients achieve pain relief using spinal analgesics, with a minimum of complications that are easily managed at home. A variety of opioids, local anesthetics, clonidine, ketamine, and other analgesics are available for the spinal route of administration and should be titrated to clinical effect or intolerable side effect. This article discusses the appropriate selection of patients for spinal analgesics, reviews current recommended infusion systems and current spinal analgesics, discusses possible complications, and includes practical suggestions for patient management.
大多数癌症疼痛患者使用传统镇痛药和辅助药物可获得良好的镇痛效果;然而,有一小部分重要患者(2%至5%)患有严重且难治性癌症疼痛。对于这些患者,脊髓镇痛药(鞘内或硬膜外给药)为长达数月或数年的治疗过程中的疼痛缓解带来了显著希望,有助于提高生活质量。脊髓镇痛药已被建议作为世界卫生组织癌症疼痛管理指南中的第四步,因此疼痛科医生应熟悉其使用原则。大多数患者使用脊髓镇痛药可实现疼痛缓解,且并发症最少,在家中即可轻松处理。有多种阿片类药物、局部麻醉药、可乐定、氯胺酮及其他镇痛药可用于脊髓给药途径,应根据临床效果或无法耐受的副作用进行滴定。本文讨论了脊髓镇痛药适用患者的恰当选择,回顾了当前推荐的输注系统和现有的脊髓镇痛药,讨论了可能的并发症,并给出了患者管理的实用建议。